D

DotBio

12 employees

DotBio develops multi-functional antibodies based on its proprietary DotBody technology as the next generation of cancer therapies.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Medical
Oncology and DotBody technology
Life Science

Date founded

2018

Funding rounds raised

Total raised

$5.6M

from 1 investors over 1 rounds

D

DotBio raised $5.6M on August 7, 2023

Investors: AIM-HI Accelerator Fund

FAQ